International multi-site collaboration hub will implement new clinical imaging tools and deliver several projects per year... read more
Mon, 06/4/18 - 11:15 am
- Keytruda was studied as monotherapy
- Overall response rate of 18.7%
- In patients whose tumors expressed PD-L1 overall response rate was 35.7%
Merck (NYSE: MRK),... read more
Mon, 06/4/18 - 09:12 am
- Median overall survival for combination 33.6 months vs 16.9 for control
- Two year overall survival was 58%
- Results selected for “Best of ASCO” program
Pierre... read more
Mon, 06/4/18 - 08:54 am
Pfizer Inc. (NYSE:PFE) announced on 6/1/2018 the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion, recommending marketing... read more
Fri, 06/1/18 - 09:56 am
- 10 new cohorts added
- 8 cohorts added in January of 2018
- Trial could include up to 640 patients total
Exelixis, Inc. (Nasdaq:EXEL) announced on 6/1/2018 an... read more
Fri, 06/1/18 - 09:37 am